Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC

Not Applicable

Completed

• Conditions: Candidiasis, Oral; HIV Infections

• Registration Number: NCT00002057
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prevention of oral candidiasis in patients with AIDS or AIDS related complex (ARC) (group III or IV, CDC classification).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Status Verified: 2007-10
• Last Update Submitted: 2007-10-01
• Last Update Posted: 2007-10-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (2)

Birmingham Veterans Administration Med Ctr / Univ of Alabama; 🇺🇸 Birmingham, Alabama, United States

Bristol - Myers Squibb Co; 🇺🇸 Princeton, New Jersey, United States